Amid policy and pricing headwinds, US healthcare and life sci faces 'vast field of opportunity': survey
As regulatory, pricing and policy dynamics whipsaw in the United States, healthcare and life sciences firms are facing enormous pressures to keep profits rising, with those challenges now “becoming As regulatory, pricing and policy dynamics whipsaw in the United States, healthcare and life sciences firms are facing enormous pressures to keep profits rising, with those challenges now “becoming more acute by the quarter,” according to an inaugural industry distress survey from consulting firm AlixPartners. Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending…

As regulatory, pricing and policy dynamics whipsaw in the United States, healthcare and life sciences firms are facing enormous pressures to keep profits rising, with those challenges now “becoming more acute by the quarter,” according to an inaugural industry distress survey from consulting firm AlixPartners.
Source: FiercePharma